Blood Testing Market Growth Driven by Precision Diagnostics

Blood Testing Market Size to Hit USD 147.61 Billion by 2030 as Roche and AIIMS Advance Precision Diagnostics 

The global Blood Testing Market is entering a new expansion phase after Roche secured CE Mark approval for its Elecsys pTau217 Alzheimer’s blood test, while All India Institute of Medical Sciences launched a low-cost precision blood testing program aimed at improving epilepsy treatment outcomes in India. The twin developments are accelerating global demand for minimally invasive diagnostics, neurological biomarker testing, and precision medicine technologies.

According to the latest proprietary analysis from Next Move Strategy Consulting, the global blood testing market size was valued at USD 91.31 billion in 2023 and is projected to reach USD 147.61 billion by 2030, expanding at a CAGR of 7.1% from 2024 to 2030. Industry analysts say the latest breakthroughs in biomarker-based neurological diagnostics and affordable therapeutic drug monitoring are reshaping the future of laboratory medicine.

The market momentum intensified this week after Roche announced CE Mark approval for Elecsys pTau217, a blood-based diagnostic assay developed in collaboration with Eli Lilly and Company. The test is designed to measure phosphorylated Tau (pTau) 217 protein, a critical biomarker associated with amyloid pathology and Alzheimer’s disease progression.

Roche executives stated that the blood test enables clinicians to rule in or rule out amyloid pathology using standardized cutoffs across both primary and secondary care settings. The development is viewed as a major industry milestone because existing Alzheimer’s diagnostic methods such as PET scans and cerebrospinal fluid analysis remain expensive, invasive, and difficult to access at scale.

“The launch of pTau217 represents a structural shift in neurological diagnostics,” said Sikha Haritwal, Research Analyst at Next Move Strategy Consulting. “According to the latest NMSC proprietary dataset, blood-based biomarker testing has seen a sharp rise in investment activity over the last two quarters due to increasing pressure on healthcare systems to deliver faster and more affordable neurodegenerative disease screening.”

Healthcare researchers estimate that nearly 41 million dementia cases globally remain undiagnosed, accounting for almost 75% of individuals living with dementia worldwide. Analysts believe scalable blood-based diagnostics could significantly reduce diagnosis delays and improve access to early intervention therapies.

AIIMS Pushes Affordable Precision Blood Testing in India

At the same time, AIIMS New Delhi launched a low-cost Therapeutic Drug Monitoring (TDM) facility focused on epilepsy care personalization. The initiative allows neurologists to monitor blood concentrations of widely used anti-epileptic medicines including levetiracetam and lamotrigine.

Doctors involved in the project stated that the technology can help determine whether medication levels are too low to prevent seizures or high enough to trigger severe side effects such as dizziness, excessive sedation, liver toxicity, and behavioral complications.

The facility became operational this week and is currently being offered free of cost, with officials indicating that future pricing will remain heavily subsidized under institutional healthcare policies. Comparable testing in private laboratories can reportedly cost between ₹6,000 and ₹10,000 per drug, limiting accessibility for long-term epilepsy patients.

“NMSC researchers identified strong growth in affordable precision diagnostics across Asia-Pacific during the last six months,” Haritwal added. “Emerging healthcare systems are increasingly prioritizing localized laboratory innovation, AI-enabled pathology workflows, and individualized treatment models.”

Neurological Diagnostics Become a Major Market Catalyst

The blood testing industry is rapidly evolving from traditional pathology services toward predictive and precision healthcare applications. Neurological disease detection, oncology biomarkers, and therapeutic drug monitoring are becoming high-growth segments within the broader diagnostics ecosystem.

Healthcare institutions are increasingly adopting blood-based diagnostics due to their lower procedural burden, faster turnaround times, and scalability compared to imaging-based or invasive diagnostic procedures.

Recent Industry Developments Driving Market Growth

Regional Outlook Highlights Asia-Pacific Growth Surge

North America currently dominates the global blood testing market due to advanced healthcare infrastructure, strong reimbursement systems, and rapid integration of AI-supported laboratory technologies. Europe remains a major innovation hub following regulatory approvals for advanced biomarker tests.

However, Asia-Pacific is expected to witness the fastest growth through 2030, driven by increasing healthcare digitization, government-supported diagnostics expansion, and rising chronic disease prevalence.

Regional Market Outlook

Competitive Landscape Intensifies

Major companies operating in the blood testing market are increasing investment in AI-assisted diagnostics, biomarker discovery, and decentralized laboratory infrastructure to strengthen competitive positioning.

Key players shaping the industry include:

• Trividia Health,  

• Siemens Healthcare,

• Anaher Corporation

• Biorad Laboratories

• AXIM Biotechnologies Inc

What CEOs and Investors Should Do Next

• Increase investment in neurological biomarker testing platforms and AI-assisted pathology solutions. 

• Expand strategic partnerships with hospitals and public healthcare systems focused on precision medicine. 

• Prioritize scalable blood-based diagnostics capable of reducing dependency on costly imaging procedures. 

• Monitor regulatory approvals related to Alzheimer’s and neurodegenerative disease biomarkers across Europe and Asia-Pacific. 

• Strengthen regional laboratory networks to support decentralized and affordable testing demand. 

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes NMSC different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more information, please contact:

Next Move Strategy Consulting

5th Floor 867

Boylston St, STE 500,

Boston, MA 02116, U.S.

E-Mail: [email protected]

Direct: +1-217-650-7991

Website: www.nextmsc.com